1. Newsroom
  2. The vaccine disrupting the pharma industry
Menu
Expertise 14.04.2021

The vaccine disrupting the pharma industry

The vaccine disrupting the pharma industry

UBP talks to Stéphane Bancel, Moderna CEO, to learn how the mRNA technology not only made one of the first COVID-19 vaccines possible, but, more importantly for investors, has the potential to disrupt the broader pharmaceutical industry in its wake.


Stéphane Bancel, the CEO of Moderna, joined UBP’s own experts in an exclusive client webinar exploring how the recently launched COVID-19 vaccines will shape the future of health and investments. In a lively discussion with Norman Villamin, UBP’s Chief Investment Officer Wealth Management, and Pierre Corby, Equity Analyst Healthcare, the discussion explored how the innovative mRNA vaccine development approach combines healthcare and technology with potentially disruptive effects for the pharmaceutical industry.

While there are several COVID-19 vaccines in production by now, Stéphane shared with our audience what it is that sets Moderna’s vaccine apart, namely the messenger ribonucleic acid (mRNA) foundation upon which it was developed. Amidst a worsening global pandemic, this technology has allowed Moderna to shorten the time to market of its vaccine dramatically compared with traditional vaccine development cycles.

For laypersons, mRNA can be thought of like a line of computer programming code for the human body. By adjusting the ‘code’, the mRNA approach allows Moderna to develop new treatments much faster and with a higher success rate than methods used by traditional pharmaceutical companies which rely on approaches that typically take several years to come to fruition, if successful at all. Indeed, Moderna sees itself as a technology company at least as much as a healthcare company, and mRNA as a product platform that has come of age.

As the global population is still grappling with the impact of the pandemic, mRNA technology has helped prevent this pandemic from lasting even longer than it already does. For investors, however, the mRNA platform for the development of therapeutics may disrupt the staid pharmaceutical industry, just as the internet disrupted stable bastions in the media and retail sectors.

Risk factors

Inevitably, with new technologies come concerns about unanticipated risks. In our active Q&A sessions with clients in attendance, there were many who voiced concerns that changing the body’s cellular ‘code’ might trigger unexpected side effects. Stéphane Bancel detailed Moderna’s safety protocols, highlighting that the mRNA molecule is destroyed within 48 hours of being injected into the body, while the lipid particle of the vaccine disappears within 24 hours, meaning that it cannot alter the body’s DNA.

Understandably, with the audience joining in from all parts of the globe, worries about the growing number of variants came up. Moderna’s CEO pointed out that it is no coincidence that several of these new strains emerged in densely populated regions afflicted by high levels of compromised immune systems. However, he showed himself cautiously optimistic that the rapid development cycle of the mRNA technology can help here, as it allows for adapting the vaccine relatively quickly to new variants.

The challenges ahead

The biggest challenge facing all vaccine makers right now is how to ramp up large-scale production. The numbers speak for themselves: Moderna went from producing 100,000 shots in 2020 to committing to providing up to one billion doses in the course of 2021. In no other industrial sector can companies claim to have achieved similarly exponential growth.

In fact, according to Stéphane Bancel, failing to invest in the scaling up of vaccine production is one of the two strategic mistakes the EU has made, along with betting on large companies that were committed to old technology.

As a result, as of the end of February 2021, Moderna had shipped 55 million doses of its vaccine to the US, but just 5 million to the European Union. Although Europe is addressing these shortcomings now, the continent will keep feeling the consequences of last year’s inaction for a while longer, since it takes about six months to build up capacity.

On the business front, the mRNA approach should accelerate new vaccine and drug development timetables and serve as a disruptive technology for the wider pharmaceuticals space.

Indeed, it doesn’t appear too far-fetched to think that the scramble for COVID-19 vaccines may have set in motion a new approach to tackling viral illnesses, paving the way for profound changes in the pharmaceutical industry and public health policies alike.

Our investment views

Villamin_Norman_150x150.jpg
Norman Villamin
Chief Investment Officer (CIO)
Wealth Management
Go to his Linkedin profile.

Corby_Pierre_150x150.jpg
Pierre Corby
Healthcare Equity Specialist
Go to his Linkedin profile.

Expertise

Gestion discrétionnaire – vous êtes toujours aux commandes

Parce que vos objectifs sont uniques, nous vous proposons un service de gestion discrétionnaire exclusif.

Lire plus
Expertise

Swiss & Global Equities

Why Swiss equities now? This market offers equity investors the stability and agility they need to navigate this volatile period. 

Read more
Expertise

European Equities

European equities offer unrivalled opportunities in terms of breadth of sector and market exposure.

Read more

Actualités les plus lues

Expertise 10.02.2021

Covid-19: Restez informés avec l'UBP

Depuis l’apparition du coronavirus, l’UBP accompagne et soutient ses clients dans le contexte inédit de cette crise sanitaire mondiale. La Banque vous informe régulièrement de l’adaptation de ses dispositifs aux règles de précaution fixées par les autorités et partage avec vous les dernières analyses de ses experts sur les conséquences de la pandémie pour l’économie mondiale et les marchés financiers.

Expertise 17.12.2020

UBP Investment Outlook 2021

Le Meilleur des Mondes

Expertise 24.11.2020

Des joyaux cachés parmi les SMID Caps suisses et européennes

Les sociétés de petite et moyenne capitalisation («SMID Caps») affichent traditionnellement des taux de croissance et des rendements supérieurs sur le long terme en comparaison des grandes capitalisations. Il est en effet plus facile de générer une croissance dynamique à partir d’une plus petite structure. Par ailleurs, les SMID Caps suisses et européennes offrent généralement aux investisseurs une exposition idéale aux grandes tendances de croissance séculaires.


A lire également

Expertise 06.05.2021

Why the Japanese market is performing well again

Japan’s equity markets have outpaced other major developed market equities in both 2020 and year-to-date in 2021 as the world seeks to transition to a post-pandemic recovery.

Expertise 04.05.2021

Positive performance defies volatile markets

The first quarter of 2021 was positive for most asset classes. However, financial markets were far from calm.

Expertise 29.04.2021

A defining moment for companies tackling climate change

The year 2021 may well turn out to be decisive for climate action.